The impact of drugs for multiple sclerosis on sleep

G Lanza, R Ferri, R Bella, L Ferini-Strambi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Although there is a growing literature on the presence of sleep disorders in multiple sclerosis (MS), few studies have specifically addressed the impact of drugs on sleep of these patients. Moreover, even when sleep is considered, quantitative assessment by standardized questionnaires or polysomnography is lacking. The studies that have been done highlight that interferon-beta and some symptomatic medications may affect sleep, thus contributing to fatigue, depression, and poor quality of life; conversely, natalizumab and cannabinoids may improve sleep. Common limitations of the literature reviewed here are small sample size, selection bias, and often a lack of objective outcome measures. Clinicians need to remember to ask about sleep in all MS patients and intervene when appropriate. A systematic approach that takes sleep into account is recommended to enhance recognition and appropriate management of sleep disruption, including disorders related to medication. Consideration of the impact on sleep should also be part of the design of trials of new therapies. © The Author(s), 2016.
Original languageEnglish
Pages (from-to)5-13
Number of pages9
JournalMultiple Sclerosis
Volume23
Issue number1
DOIs
Publication statusPublished - 2017

Fingerprint

Multiple Sclerosis
Sleep
Pharmaceutical Preparations
Cannabinoids
Selection Bias
Polysomnography
Interferon-beta
Sample Size
Fatigue
Quality of Life
Outcome Assessment (Health Care)
Depression

Cite this

The impact of drugs for multiple sclerosis on sleep. / Lanza, G; Ferri, R; Bella, R; Ferini-Strambi, L.

In: Multiple Sclerosis, Vol. 23, No. 1, 2017, p. 5-13.

Research output: Contribution to journalArticle

@article{dece3f15aa854da7a62b2f74372fd102,
title = "The impact of drugs for multiple sclerosis on sleep",
abstract = "Although there is a growing literature on the presence of sleep disorders in multiple sclerosis (MS), few studies have specifically addressed the impact of drugs on sleep of these patients. Moreover, even when sleep is considered, quantitative assessment by standardized questionnaires or polysomnography is lacking. The studies that have been done highlight that interferon-beta and some symptomatic medications may affect sleep, thus contributing to fatigue, depression, and poor quality of life; conversely, natalizumab and cannabinoids may improve sleep. Common limitations of the literature reviewed here are small sample size, selection bias, and often a lack of objective outcome measures. Clinicians need to remember to ask about sleep in all MS patients and intervene when appropriate. A systematic approach that takes sleep into account is recommended to enhance recognition and appropriate management of sleep disruption, including disorders related to medication. Consideration of the impact on sleep should also be part of the design of trials of new therapies. {\^A}{\circledC} The Author(s), 2016.",
author = "G Lanza and R Ferri and R Bella and L Ferini-Strambi",
year = "2017",
doi = "10.1177/1352458516664034",
language = "English",
volume = "23",
pages = "5--13",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - The impact of drugs for multiple sclerosis on sleep

AU - Lanza, G

AU - Ferri, R

AU - Bella, R

AU - Ferini-Strambi, L

PY - 2017

Y1 - 2017

N2 - Although there is a growing literature on the presence of sleep disorders in multiple sclerosis (MS), few studies have specifically addressed the impact of drugs on sleep of these patients. Moreover, even when sleep is considered, quantitative assessment by standardized questionnaires or polysomnography is lacking. The studies that have been done highlight that interferon-beta and some symptomatic medications may affect sleep, thus contributing to fatigue, depression, and poor quality of life; conversely, natalizumab and cannabinoids may improve sleep. Common limitations of the literature reviewed here are small sample size, selection bias, and often a lack of objective outcome measures. Clinicians need to remember to ask about sleep in all MS patients and intervene when appropriate. A systematic approach that takes sleep into account is recommended to enhance recognition and appropriate management of sleep disruption, including disorders related to medication. Consideration of the impact on sleep should also be part of the design of trials of new therapies. © The Author(s), 2016.

AB - Although there is a growing literature on the presence of sleep disorders in multiple sclerosis (MS), few studies have specifically addressed the impact of drugs on sleep of these patients. Moreover, even when sleep is considered, quantitative assessment by standardized questionnaires or polysomnography is lacking. The studies that have been done highlight that interferon-beta and some symptomatic medications may affect sleep, thus contributing to fatigue, depression, and poor quality of life; conversely, natalizumab and cannabinoids may improve sleep. Common limitations of the literature reviewed here are small sample size, selection bias, and often a lack of objective outcome measures. Clinicians need to remember to ask about sleep in all MS patients and intervene when appropriate. A systematic approach that takes sleep into account is recommended to enhance recognition and appropriate management of sleep disruption, including disorders related to medication. Consideration of the impact on sleep should also be part of the design of trials of new therapies. © The Author(s), 2016.

U2 - 10.1177/1352458516664034

DO - 10.1177/1352458516664034

M3 - Article

VL - 23

SP - 5

EP - 13

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 1

ER -